← Back to Search

Cohort 1 for Non-Small Cell Lung Cancer

N/A
Recruiting
Led By Anjali Avadhani, MD
Research Sponsored by Tempus AI
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

Non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-Free Survival
Recurrence-Free Survival
Secondary outcome measures
Positive Predictive Value
Sensitivity
Specificity
Other outcome measures
Lead Time
Overall Survival

Side effects data

From 2016 Phase 3 trial • 356 Patients • NCT00048997
31%
Fatigue (lethargy, malaise, asthenia)
23%
Alopecia
17%
Late RT Toxicity: Other: NOS
11%
Nausea
10%
Anorexia
9%
Late RT Toxicity: Brain: NOS
9%
Headache
7%
Late RT Toxicity: Skin: NOS
6%
Memory loss
1%
Dyspnea (shortness of breath)
1%
Mood alteration-depression
1%
Hemorrhage-Other
1%
Ataxia (incoordination)
1%
Pain-Other
100%
80%
60%
40%
20%
0%
Study treatment Arm
Prophylactic Cranial Irradiation (PCI)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2Experimental Treatment1 Intervention
Cohort 2 will include patients with stage IV disease receiving first line IO (mono/combo) therapy.
Group II: Cohort 1Experimental Treatment1 Intervention
Cohort 1 will include patients with early-stage and locally advanced disease (stages I-IIIB) who are candidates for definitive surgical resection.

Find a Location

Who is running the clinical trial?

AstraZenecaIndustry Sponsor
4,265 Previous Clinical Trials
288,604,469 Total Patients Enrolled
Tempus AILead Sponsor
16 Previous Clinical Trials
16,726 Total Patients Enrolled
Tempus LabsLead Sponsor
16 Previous Clinical Trials
17,226 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Mayo Clinic ProceedingsJournal
Non–small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, Narjust, Rafael Santana-Davila, and Julian R. Molina. 2019. “Non–small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment”. Mayo Clinic Proceedings. Elsevier BV. doi:10.1016/j.mayocp.2019.01.013.
Clinical Cancer ResearchJournal
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Leighl, Natasha B., Ray D. Page, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, et al.. 2019. “Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer”. Clinical Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/1078-0432.ccr-19-0624.
JNCI Journal of the National Cancer InstituteJournal
Sequential Vs Concurrent Chemoradiation for Stage III Non-small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
Curran, W. J., R. Paulus, C. J. Langer, R. Komaki, J. S. Lee, S. Hauser, B. Movsas, et al.. 2011. “Sequential Vs Concurrent Chemoradiation for Stage III Non-small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410”. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP). doi:10.1093/jnci/djr325.
Cancer Treatment ReviewsJournal
Immunotherapy in Non-small Cell Lung Cancer Harbouring Driver Mutations
Addeo, Alfredo, Antonio Passaro, Umberto Malapelle, Giuseppe Luigi Banna, Vivek Subbiah, and Alex Friedlaender. 2021. “Immunotherapy in Non-small Cell Lung Cancer Harbouring Driver Mutations”. Cancer Treatment Reviews. Elsevier BV. doi:10.1016/j.ctrv.2021.102179.
~302 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top